Aerospace Industry 16 August 2025

June 30, 2026, 8:54 PM EDT. Cadrenal Therapeutics Inc. (Nasdaq: CVKD) is raising $3 million in a private placement, with another $5.8 million tied to warrant exercise for a possible $8.8 million total. The deal covers 960,000 common shares plus series C-1 and C-2 warrants at $3.125 a share. Cadrenal plans to use the funds to extend its cash runway through early 2027, or mid-2027 if all warrants are taken, to develop therapies for Kawasaki Disease and related immune and thrombotic conditions. The placement is being done in line with Nasdaq at-the-market regulations. H.C. Wainwright & Co. is placement agent. Closing is expected by July 1, pending conditions.